Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2003
03/27/2003US20030060429 Stilbene derivatives and taxanes, vinca alkaloids, alkylating agents, antimetabolites, epidophylloptoxins, platinum compounds, and antibiotics; antitumor agents
03/27/2003US20030060428 Bicyclo (3.2.1)octane in a double ring system having a basic chemical skeletal of a kaurene structure that responds only at elevated plasma glucose concentrations
03/27/2003US20030060423 Using cyclohexyl or pyran methylenesulfamate derivatives to treat psychological disorders
03/27/2003US20030060415 Internal entry, such as through an atrium or ventricle, or can be by an external entry through the chest wall; cardiovascular therapeutics
03/27/2003US20030060401 Genetic engineered drug
03/27/2003US20030060399 A heat shock protein 20 (HSP20)-derived polypeptides for treating or inhibiting smooth muscle vasospasm, smooth muscle cell proliferation, migration, and vasoconstriction
03/27/2003US20030060397 Method of treating and preventing acute neural lesions with substances that modulate the expression or function of a protein involved in the cell cycle and pharmaceutical preparations containing such substances
03/27/2003US20030059937 Antibodies that immunospecifically bind BLyS
03/27/2003US20030059922 Sphingosine1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059871 Hematopoietin receptors HPR1 and HPR2
03/27/2003US20030059869 Novel G protein-coupled receptor, GAVE3
03/27/2003US20030059866 Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon
03/27/2003US20030059859 Vertebrate protein for use in human therapeutic and diagnostics
03/27/2003US20030059852 Detecting modulators of integrin activity; obtain sample containing integrin, incubate with test compound, monitor adjustment in integrin activity, adjustment in integrin activity indicates modulator
03/27/2003US20030059812 HDAC9 polypeptides and polynucleotides and uses thereof
03/27/2003US20030059805 Nucleotide sequences coding polyeptide for use in the treatment of growth disorders in humans
03/27/2003US20030059498 A protease and an inner salt of a quaternary amine carboxylic acid for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities; improved weight gain; poultry; Eimeria
03/27/2003US20030059481 Composition for promoting healthy bone structure
03/27/2003US20030059478 Aqueous extract of the plant Soma; a mixture of milk, plant derivatives and a mineral comprising apple cider vinegar, quinine, blackstrap molasses, sulfur and whole milk; anticarcinogenic and -tumor agents
03/27/2003US20030059472 Preparation of submicron sized nanoparticles via dispersion lyophilization
03/27/2003US20030059470 Dispersions for the formulation of slightly or poorly soluble agents
03/27/2003US20030059461 Molecular delivery vehicle for delivery of selected compounds to targets
03/27/2003US20030059430 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor
03/27/2003US20030059423 Method for treating symptoms of diabetes
03/27/2003US20030059418 Composition for prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10
03/27/2003US20030059417 Methods and compositions for diagnosing and treating disorders involving angiogenesis
03/27/2003US20030059401 Composition and method for causing photodynamic damage to target cells
03/27/2003US20030059397 Solid oral dosage forms of controlled substances having reduced potential for abuse by inhalation, mastication, and injection; for alternative administration of oxycodone
03/27/2003US20030059375 Method for treating lung cancers
03/27/2003US20030059374 Use of metoclopramide
03/27/2003US20030057193 Method for forming a via hole, flexible wiring board using the method, and method for producing the flexible wiring board
03/27/2003US20030056788 Partial liquid breathing of fluorocarbons
03/27/2003DE20219658U1 Composition for reducing body weight, contains swellable compound, preferably polysaccharide, to give satiation effect and nutrients and/or active agents for retarded release
03/27/2003CA2492826A1 Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
03/27/2003CA2466243A1 Indolizines as kinase protein inhibitors
03/27/2003CA2460987A1 Pharmaceutical formulations for protecting pharmaceutical compound from acidic environments
03/27/2003CA2460845A1 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
03/27/2003CA2460812A1 Lipid-associated molecules
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460719A1 Igf-binding protein-derived peptide or small molecule
03/27/2003CA2460713A1 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
03/27/2003CA2460620A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents
03/27/2003CA2460587A1 Anti-pdgf antibodies and methods for producing engineered antibodies
03/27/2003CA2460442A1 Combination of a pde inhibitor and a leukotriene receptor antagonist
03/27/2003CA2460334A1 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003CA2460326A1 Method for treating skin disorders
03/27/2003CA2460321A1 Chemokines as adjuvants of immune response
03/27/2003CA2460151A1 Cytokine receptor
03/27/2003CA2459949A1 Retinoid receptor pan-antagonists for stimulating chondrogenesis
03/27/2003CA2459773A1 Enamel matrix protein compositions for modulating immune response
03/27/2003CA2459547A1 Method of increasing the presence of glutathione in cells
03/27/2003CA2459140A1 Protein modification and maintenance molecules
03/27/2003CA2459022A1 Neurotransmission-associated proteins
03/26/2003EP1296142A2 Calcium receptor active molecules
03/26/2003EP1295879A1 Medicinal compositions containing propenone derivatives
03/26/2003EP1295609A1 Drugs containing combined active ingredients
03/26/2003EP1295608A1 Remedial agent for anxiety neurosis or depression and piperazine derivative
03/26/2003EP1295607A1 Antitumor effect potentiators
03/26/2003EP1295601A1 Pharmaceutical composition based on a non-steroid anti-inflammatory agent
03/26/2003EP1295597A1 Antitumour compositions containing taxan derivatives
03/26/2003EP1294928A1 Screening method for modulators of suv39h2-methyltransferase
03/26/2003EP1294927A1 Screening-method for modulators of methyltransferase-dependent chromosome stability
03/26/2003EP1294922A2 Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents
03/26/2003EP1294901A2 Novel proteases
03/26/2003EP1294886A2 THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IGE ANTIBODY AND USES THEREOF
03/26/2003EP1294885A2 B7-like molecules and uses thereof
03/26/2003EP1294884A2 Secretion and trafficking molecules
03/26/2003EP1294883A2 Human extracellular matrix (ecm)-related tumor marker
03/26/2003EP1294879A2 Thymic stromal lymphopoietin receptor molecules and uses thereof
03/26/2003EP1294876A2 Eg-vegf nucleic acids and polypeptides and methods of use
03/26/2003EP1294873A1 Tumour suppressor and uses thereof
03/26/2003EP1294868A2 Adenylyl and guanylyl cyclases
03/26/2003EP1294867A1 Human site-1 protease promoter
03/26/2003EP1294856A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
03/26/2003EP1294808A2 Fast cure film forming formulation
03/26/2003EP1294770A1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
03/26/2003EP1294769A1 Antibodies that immunospecifically bind to blys
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294759A1 Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen
03/26/2003EP1294754A1 Interferon-alpha induced gene
03/26/2003EP1294753A2 A human homologue of the db4/ask1 protein, nucleic acids, and methods related to the same
03/26/2003EP1294752A2 Angiogenesis-modulating compositions and uses
03/26/2003EP1294751A1 Dermacentor variabilis gaba-gated chloride channels
03/26/2003EP1294750A2 Acid-modified arabinogalactan protein composition
03/26/2003EP1294745A2 Antimicrobial peptides and methods of use thereof
03/26/2003EP1294728A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD
03/26/2003EP1294724A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
03/26/2003EP1294695A2 Substituted diamide derivatives useful as motilin antagonists
03/26/2003EP1294689A1 Novel $g(b crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
03/26/2003EP1294682A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
03/26/2003EP1294422A1 Methods and systems for enhancing fluid flow through an obstructed vascular site
03/26/2003EP1294411A1 A novel treatment for cough
03/26/2003EP1294401A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
03/26/2003EP1294398A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
03/26/2003EP1294397A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
03/26/2003EP1294395A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR
03/26/2003EP1294394A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR
03/26/2003EP1294392A2 Materials and methods relating for the treatment and diagnosis of pre-eclampsia
03/26/2003EP1294391A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
1 ... 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 ... 1151